Example of the quantification process: red, green, and blue channels were combined into a single 8-bit image and the area was then assessed. The muscularis mucosae was excluded (red area in right panel). c) Quantification for n=23 tumours from n=9 wt mice; adjacent mucosal areas were used in pairwise comparisons to account for staining heterogeneity; p=0.61 (paired t-test). Fig. 2 ) during 3 cycles of DSS. Only mice that reached the endpoint are shown (n=5 Ihh Vil mice and n=11 controls). Weight on days 35-40 and 59-64 was significantly different, p < 0.05 (t-test without multiple-test correction). d) Survival curves for all mice in this experiment (n=13 Ihh Vil mice and n=11 controls); the first course of DSS was associated with increased mortality in the Ihh  Vil group; log-rank p=0.0019. For the subsequent DSS cycles, the concentration of DSS was lowered from 1.75% to 1.25%, after which no further mortality was observed (described in more detail in Methods). e) Relative gene expression for the indicated transcripts from wt mice treated with vismodegib, 25 mg/kg bodyweight twice daily (n=3) or vehicle (DMSO, n=3), p=0.0096 (Gli1), p=0.11 (Hhip), p=0.11 (Ptch1), p<0.0001 (Ptch2, all t-
tests, fdr-adjusted). f) Weight curves during AOM/DSS treatment of mice treated with vismodegib or vehicle (related to figure 2f). Weight was different only on day 9 (p=0.023; t-test without multiple-test correction). g) Survival curves, related to (f). Differences were not significant (log-rank p=0.12)
Supplementary Figure 4
Gli1-expressing cells in DSS colitis a) Schematic of the protocol: 3% DSS was given for 5 days, Gli1 lacZ/+ mice (n=3) were sacrificed on day 6 (stage of active colitis), Gli1CreER T2 ;R26-LSL-tdTomato mice (n=3) were injected with 5 mg Tam i.p. on day 6 and sacrificed 72h later. b) Confocal image of tdTomato fluorescence and staining with antibodies against Collagen 1 (blue, stroma) and It6 (green, epithelium). Scale bars 100/20µm; representative of n=3 mice; epithelial tdTomato fluorescence was never observed. c) Representative histology (H&E and X-gal staining) of a Gli1 lacZ/+ mouse with acute colitis and d) a littermate Gli1 lacZ/+ mouse that received regular drinking water. Epithelial X-gal staining was never observed. Scale bars 200/50µm; representative of n=3 mice.
Supplementary Figure 5 Differences between localised and systemic activation of Col1a2CreER
Comparison of Cre-mediated recombination between inducible Col1a2CreER;R26-LSLtdTomato reporter mice injected with corn oil (a), injected intraperitoneally (i.p.) with tamoxifen (b) or given 4OH-tamoxifen transrectally (t.r.) (c) at 10 weeks of age (related to Figure 3e ). The systemic administration of 5 mg Tam led to recombination in many organs, including colon, kidney, lung, and liver. In the i.p.-treated animals, Tomato + cells were associated with kidney glomeruli, widely distributed in the lung, and located predominantly around the major bile ducts in the liver, while upon t.r. administration, recombination is most frequent in the colon; note that i.p. administration is associated with higher recombination frequency in the muscularis externa (oblique longitudinal cells in b, magnified insets). Animals were sacrificed 7 days after Tam treatment. Images representative of n=7 i.p.-treated animals, n=7 i.r.-treated mice, and n=4 oiltreated controls. Images were acquired with a Zeiss SteREO Discovery.V20 microscope with a 0.63X lens at minimum zoom (resulting in 4.7x magnification), taken with an AxioCam MR3 camera and Zeiss Zen 2012 software v 1.1.1.0.
Supplementary Figure 6
Ptch1 Col(het) mice after treatment with AOM/DSS a) Weight curves of n=12 Ptch1 Col1(het) mice compared to n=12 littermate controls (lacking the Cre allele, the floxed Ptch1 allele or both); day 0: AOM injection (related to Fig. 4) . Weight was significantly different on day 17 only (p=0.022; t-tests without correction for multiple testing). Survival was not significantly different (not shown). b) Immune cell abundance in non-malignant mucosa of the indicated genotypes at the endpoint of the AOM/DSS protocol; p=0.805 (Cd3); p=0.915 (B220); p=0.805 (Mpo); p=0. 805 (F4/80; all t-tests; adjusted p-values [fdr] are presented). Box-and-whisker plots, whiskers represent minima and maxima. IHC for a subset of n=6 Ptch1 Col1(het) mice and n=7 controls (as defined in a). c and d): Fluorescence RNA ISH for Gli1 mRNA in c) control mice (related to Fig, 4b ) and d) Ptch1 Col1(het) mice. Gli1 expression was observed in the stroma of Ptch1 Col1(het) mice (arrowheads, dashed line indicates epithelial border); scale bars: 200/50 µm. e) Quantification of stromal content with triple-IF (as described in Supplementary Fig. 1 ), for n=20 tumours from n=6 littermate controls and n=12 tumours from n=6 Ptch1 Col1(het) mice; p=0.158, t-test.  Col1 mice and n=9 controls (lacking Cre recombinase). Differences were significant on days 39 (p=0.037), 41 (p=0.011), and 43 (p=0.004; all t-tests without correction for multiple testing). d) Survival curves; log-rank p=0.0002. One Ptch1  Col1 mouse was found dead on day 3 after Tam treatment (t.r.); one Ptch1  Col1 mouse was sacrificed due to self-inflicted wounds (day 42, not counted as experiment-related event). The other mice were sacrificed following ethical guidelines. e) H&E staining of a colon section from a Ptch1  Col1 mouse sacrificed on day 16 (1 st cycle of DSS-colitis) due to severe weight loss and bloody diarrhoea. Note the almost complete destruction of the epithelial lining (magnification) as well as stromal proliferation (asterisks, related to panels f and g). Scale bars: 200/50 µm. f) Macroscopic appearance of a large, cystic stromal tumour (white dashed line) in a 6 month old female Ptch1  Col1 mouse, diagnosed 8 days after application of 4OH-Tam t.r. g) RNA ISH and hematoxylin staining of the tumour in (d) showing high Gli1 expression in the stromal tumour.
Supplementary Figure 7

Supplementary Figure 8
Correlation of GLI1 expression with driver mutations and stromal gene signatures a) Correlation of GLI1 mRNA levels with the presence of KRAS, BRAF, and APC mutations; a weak correlation was observed between APC mutations and low GLI1 expression (p-values indicated above the panels). NB: For this analysis, gene expression data were extracted from the TCGA COAD Illumina RNA-seq dataset and correlated to the Illumina mutation data set, as the mutation data corresponding to the Agilent data used for all other TCGA analysis was limited to 53 samples. b) Correlation of GLI1 to stromal gene expression signatures as defined by the ESTIMATE algorithm. A strong positive correlation was observed for GLI1 and tumour stroma content ("ESTIMATE", left panel, score combines "stromal" and "immune" cell markers). This robust association appeared to be dominated by a very strong correlation between GLI1 and non-immune cell markers (middle panel, "stromal" gene expression), while genes thought to be expressed predominantly in immune cells contributed to a lesser extent (right panel, "immune" gene expression). Correlation coefficients and p-values are indicated above the panels.
Supplementary Figure 9
Invasive tumours in mice treated with AOM/DSS Representative examples of invasive tumours from wt C57BL/6 mice at the endpoint of the AOM/DSS protocol. In a), the muscularis mucosae appears discontinuous (arrows in magnified image, right panel), while in b), malignant cells are found below the muscularis mucosae, together with desmoplastic stroma and mucus lakes, strongly indicating invasiveness. Scale bars 200/50 µm (a), 500/100 µm (b). Gene set derived from GO term 0030514, "negative regulation of BMP signaling pathway", filter settings as described in Materials & Methods 
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